Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection
Phase 1
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002078
- Lead Sponsor
- Purdue Frederick
- Brief Summary
To determine the safety and tolerance of subcutaneous injections of natural interferon alpha (IFN) in asymptomatic HIV-positive persons and record its effects on the HIV virus in these individuals.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does natural interferon alpha (IFN) modulate in asymptomatic HIV-1 infection to suppress viral replication?
How does subcutaneous Alferon N compare to standard HAART in early HIV-1 treatment regarding virological and immunological outcomes?
Which biomarkers correlate with response to interferon alpha (IFN) therapy in asymptomatic HIV-1 patients?
What are the safety profiles and management strategies for subcutaneous interferon alpha (IFN) in asymptomatic HIV-1 patients?
What combination therapies with interferon alpha (IFN) have shown efficacy in asymptomatic HIV-1 treatment compared to monotherapy?
Trial Locations
- Locations (2)
Walter Reed Army Institute of Research
🇺🇸Washington, District of Columbia, United States
Natl Naval Med Ctr
🇺🇸Bethesda, Maryland, United States
Walter Reed Army Institute of Research🇺🇸Washington, District of Columbia, United States